WO1999063945A3 - Vaccination strategy to prevent and treat cancers - Google Patents

Vaccination strategy to prevent and treat cancers Download PDF

Info

Publication number
WO1999063945A3
WO1999063945A3 PCT/US1999/013146 US9913146W WO9963945A3 WO 1999063945 A3 WO1999063945 A3 WO 1999063945A3 US 9913146 W US9913146 W US 9913146W WO 9963945 A3 WO9963945 A3 WO 9963945A3
Authority
WO
WIPO (PCT)
Prior art keywords
mhc
immunogenic
target protein
therapeutic antigen
immune
Prior art date
Application number
PCT/US1999/013146
Other languages
French (fr)
Other versions
WO1999063945A2 (en
Inventor
Janko Nikolic-Zugic
Ruben Dyall
Alan N Houghton
Original Assignee
Sloan Kettering Inst Cancer
Nikolic Zugic Janko
Ruben Dyall
Alan N Houghton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Nikolic Zugic Janko, Ruben Dyall, Alan N Houghton filed Critical Sloan Kettering Inst Cancer
Priority to EP99930206A priority Critical patent/EP1085892A4/en
Priority to CA002331378A priority patent/CA2331378A1/en
Publication of WO1999063945A2 publication Critical patent/WO1999063945A2/en
Publication of WO1999063945A3 publication Critical patent/WO1999063945A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A cellular immune response is induced to a non-immunogenic or weakly immunogenic target protein expressed by tumor cells, by administering to a mammalian subject an amount of a therapeutic antigen effective to induce a cellular immune response to the target protein. The therapeutic antigen is an immunogenic peptide having an MHC-binding portion which binds to the major histocompatibility complex (MHC) and an immune-recognition portion which is recognized by T-cells. The therapeutic antigen is derived from the non-immunogenic or weakly immunogenic target protein such that the MHC-binding portion binds to MHC with a greater affinity than the target protein without material alteration of the immune-recognition portion. The therapeutic antigen may include a sorting signal which directs the transport of the therapeutic antigen into the endoplasmic reticulum and into the endosome/lysosome to facilitate loading of the peptide onto MHC class I and class II molecules, respectively, to facilitate loading of the protein onto MHC molecules for presentation to the immune system.
PCT/US1999/013146 1998-06-12 1999-06-11 Vaccination strategy to prevent and treat cancers WO1999063945A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99930206A EP1085892A4 (en) 1998-06-12 1999-06-11 Vaccination strategy to prevent and treat cancers
CA002331378A CA2331378A1 (en) 1998-06-12 1999-06-11 Vaccination strategy to prevent and treat cancers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8905598P 1998-06-12 1998-06-12
US60/089,055 1998-06-12
US10633998P 1998-10-30 1998-10-30
US60/106,339 1998-10-30

Publications (2)

Publication Number Publication Date
WO1999063945A2 WO1999063945A2 (en) 1999-12-16
WO1999063945A3 true WO1999063945A3 (en) 2000-03-02

Family

ID=26780171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013146 WO1999063945A2 (en) 1998-06-12 1999-06-11 Vaccination strategy to prevent and treat cancers

Country Status (3)

Country Link
EP (1) EP1085892A4 (en)
CA (1) CA2331378A1 (en)
WO (1) WO1999063945A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
JP2002509716A (en) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション Methods and compositions for raising an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
JP2004527449A (en) 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Universal vaccine and method for treating cancer using telomerase reverse transcriptase
HU229377B1 (en) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogenic human peptides
WO2002066515A1 (en) * 2001-02-23 2002-08-29 Institut Pasteur Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDERSON ET AL.: "Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to Clas I-restricted cell-mediated lysis", J. EXP. MED.,, vol. 174, August 1991 (1991-08-01), pages 489 - 492, XP002924218 *
RAMMENSEE ET AL.: "MHC ligands and peptide motifs: first listing", IMMUNOGENETICS,, vol. 41, 1995, pages 178 - 228, XP000673045 *
ROGERS ET AL.: "Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response", J. IMMUNOL.,, vol. 160, 1998, pages 3698 - 3704, XP002924217 *
SETTE ET AL.: "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes", J. OF IMMUNOL.,, vol. 153, 1994, pages 5586 - 5592, XP002088728 *
WOELFEL ET AL.: "Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes", EUR. J. IMMUNOL.,, vol. 24, 1994, pages 759 - 764, XP002924220 *
YEWDELL ET AL.: "MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation", J. IMMUNOL.,, vol. 152, 1994, pages 1163 - 1170, XP002924219 *

Also Published As

Publication number Publication date
WO1999063945A2 (en) 1999-12-16
EP1085892A2 (en) 2001-03-28
CA2331378A1 (en) 1999-12-16
EP1085892A4 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
EP2316476A3 (en) Antigenic peptides derived from telomerase
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
WO1995029193A3 (en) Melanoma antigens
CA2290485A1 (en) Method for the production of non-immunogenic proteins
WO2001026608A3 (en) Dna vaccines encoding antigen linked to a domain that binds cd40
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
EP0679093A1 (en) Methods of delivering agents to target cells.
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
AU3192889A (en) T cell activation markers
AU7599500A (en) Novel gl50 molecules and uses therefor
Tanaka et al. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody
NO20011381L (en) Streptococcal C <beta> protein preparations
AU2741897A (en) Suppression of immune response via inhibition of cathepsin s
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
EP0722499A4 (en) Immunoreactive antigens of hepatitis e virus
DE3751319T2 (en) USE AND COMPOSITION TO IMPROVE THE "TARGETING" OF ANTIBODIES, ANTIBODY PARTS, AND CONJUGATES THEREOF.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2331378

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09719494

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999930206

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999930206

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999930206

Country of ref document: EP